F. Spyratos

2.6k total citations
52 papers, 2.0k citations indexed

About

F. Spyratos is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, F. Spyratos has authored 52 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 26 papers in Cancer Research and 24 papers in Molecular Biology. Recurrent topics in F. Spyratos's work include Breast Cancer Treatment Studies (14 papers), Estrogen and related hormone effects (11 papers) and HER2/EGFR in Cancer Research (10 papers). F. Spyratos is often cited by papers focused on Breast Cancer Treatment Studies (14 papers), Estrogen and related hormone effects (11 papers) and HER2/EGFR in Cancer Research (10 papers). F. Spyratos collaborates with scholars based in France, Belgium and United States. F. Spyratos's co-authors include K. Hacène, Rosette Lidereau, V Le Doussal, M. Tubiana-Hulin, M Brunet, J Gest, Sam Friedman, Charles Theillet, Chantal Escot and Rena D. Callahan and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

F. Spyratos

51 papers receiving 2.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
F. Spyratos France 23 1.0k 906 796 389 290 52 2.0k
Atul K. Tandon United States 13 906 0.9× 743 0.8× 652 0.8× 532 1.4× 235 0.8× 19 1.7k
Sten Wingren Sweden 24 1.0k 1.0× 701 0.8× 625 0.8× 581 1.5× 443 1.5× 63 2.1k
Maryou Lambros United Kingdom 23 1.0k 1.0× 1.4k 1.5× 902 1.1× 280 0.7× 329 1.1× 39 2.3k
Frédérique Spyratos France 24 660 0.7× 878 1.0× 788 1.0× 280 0.7× 183 0.6× 41 1.7k
J. Zujewski United States 10 1.1k 1.1× 548 0.6× 1.0k 1.3× 218 0.6× 388 1.3× 16 1.9k
A.L. Børresen-Dale Norway 20 970 1.0× 1.5k 1.6× 762 1.0× 339 0.9× 352 1.2× 41 2.4k
Ellen C.M. Mommers Netherlands 16 815 0.8× 700 0.8× 805 1.0× 180 0.5× 240 0.8× 19 1.8k
Päivikki Kauraniemi Finland 18 901 0.9× 1.4k 1.5× 492 0.6× 438 1.1× 163 0.6× 19 2.0k
Véronique Becette France 18 1.0k 1.0× 889 1.0× 983 1.2× 281 0.7× 313 1.1× 56 2.2k
Diana M. Barnes United Kingdom 28 1.8k 1.8× 1.6k 1.8× 939 1.2× 636 1.6× 478 1.6× 58 3.1k

Countries citing papers authored by F. Spyratos

Since Specialization
Citations

This map shows the geographic impact of F. Spyratos's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by F. Spyratos with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites F. Spyratos more than expected).

Fields of papers citing papers by F. Spyratos

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by F. Spyratos. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by F. Spyratos. The network helps show where F. Spyratos may publish in the future.

Co-authorship network of co-authors of F. Spyratos

This figure shows the co-authorship network connecting the top 25 collaborators of F. Spyratos. A scholar is included among the top collaborators of F. Spyratos based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with F. Spyratos. F. Spyratos is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hamy, Anne‐Sophie, Ivan Bièche, Jacqueline Lehmann‐Che, et al.. (2016). BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy. Breast Cancer Research and Treatment. 159(3). 499–511. 39 indexed citations
2.
Lehmann‐Che, Jacqueline, Véronique Scott, Bernard Asselain, et al.. (2013). Outcome impact of PIK3CA mutations in HER2-positive breast cancer patients treated with trastuzumab. British Journal of Cancer. 108(9). 1807–1809. 76 indexed citations
3.
4.
Mazouni, Chafika, F. Spyratos, S Romain, et al.. (2012). A nomogram to predict individual prognosis in node-negative breast carcinoma. European Journal of Cancer. 48(16). 2954–2961. 7 indexed citations
5.
Vacher, Sophie, A. Susini, Géraldine Cizeron-Clairac, et al.. (2012). Identification of New Candidate Therapeutic Target Genes in Triple-Negative Breast Cancer. Genes & Cancer. 3(1). 63–70. 26 indexed citations
6.
Span, Paul N., Anieta M. Sieuwerts, J.J.T.M. Heuvel, et al.. (2008). Harmonisation of multi-centre real-time reverse-transcribed PCR results of a candidate prognostic marker in breast cancer: An EU-FP6 supported study of members of the EORTC – PathoBiology Group. European Journal of Cancer. 45(1). 74–81. 2 indexed citations
7.
Tozlu, Sengül, Igor Girault, Sophie Vacher, et al.. (2006). Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocrine Related Cancer. 13(4). 1109–1120. 191 indexed citations
8.
Becette, Véronique, Catherine H. Régnier, Emmanuelle Fourme, et al.. (2004). Gene Transcript Assay by Real-Time Rt-PCR in Epithelial Breast Cancer Cells Selected by Laser Microdissection. The International Journal of Biological Markers. 19(2). 100–108. 9 indexed citations
9.
Girault, Igor, F. Lerebours, Sengül Tozlu, et al.. (2002). Real-time reverse transcription PCR assay of CYP19 expression: application to a well-defined series of post-menopausal breast carcinomas. The Journal of Steroid Biochemistry and Molecular Biology. 82(4-5). 323–332. 27 indexed citations
10.
Broët, Philippe, S Romain, A Daver, et al.. (2001). Thymidine Kinase as a Proliferative Marker: Clinical Relevance in 1,692 Primary Breast Cancer Patients. Journal of Clinical Oncology. 19(11). 2778–2787. 77 indexed citations
11.
Goff, James M., et al.. (2000). Nonlinear discriminant analysis and prognostic factor classification in node-negative primary breast cancer using probabilistic neural networks.. PubMed. 20(3B). 2213–8. 11 indexed citations
12.
Ferrero-Poüs, M., K. Hacène, C. Bouchet, et al.. (2000). Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis.. PubMed. 6(12). 4745–54. 65 indexed citations
13.
Broët, Philippe, F. Spyratos, S Romain, et al.. (1999). Prognostic value of uPA and p53 accumulation measured by quantitative biochemical assays in 1245 primary breast cancer patients: a multicentre study. British Journal of Cancer. 80(3-4). 536–545. 25 indexed citations
14.
Doussal, V Le, François Degorce, Laurent Bellanger, et al.. (1997). Comparison of a new microplate oestrogen receptor (ER) enzyme immunoassay with other ER detection methods. British Journal of Cancer. 76(4). 519–525. 2 indexed citations
15.
Broët, Philippe, H Magdelénat, J Delarue, et al.. (1996). Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. British Journal of Cancer. 73(12). 1545–1551. 114 indexed citations
16.
Spyratos, F., et al.. (1994). Prognostic value of a solubilized fraction of EGF receptors in primary breast cancer using an immunoenzymatic assay ? a retrospective study. Breast Cancer Research and Treatment. 29(1). 85–95. 13 indexed citations
17.
Spyratos, F., Charlotte Andrieu, K. Hacène, Pierre Chambon, & MC Rio. (1994). pS2 and response to adjuvant hormone therapy in primary breast cancer. British Journal of Cancer. 69(2). 394–397. 21 indexed citations
18.
Brouillet, J.P., F. Spyratos, K. Hacène, et al.. (1993). Immunoradiometric assay of pro-cathepsin D in breast cancer cytosol: Relative prognostic value versus total cathepsin D. European Journal of Cancer. 29(9). 1248–1251. 28 indexed citations
19.
20.
Spyratos, F., K. Hacène, M. Tubiana-Hulin, C. Pallud, & M Brunet. (1989). Prognostic value of estrogen and progesterone receptors in primary infiltrating ductal breast cancer. European Journal of Cancer and Clinical Oncology. 25(8). 1233–1240. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Atul K. Tandon Breakdown of academic impact, for papers by Sten Wingren Breakdown of academic impact, for papers by Maryou Lambros Breakdown of academic impact, for papers by Frédérique Spyratos Breakdown of academic impact, for papers by J. Zujewski Breakdown of academic impact, for papers by A.L. Børresen-Dale Breakdown of academic impact, for papers by Ellen C.M. Mommers Breakdown of academic impact, for papers by Päivikki Kauraniemi Breakdown of academic impact, for papers by Véronique Becette Breakdown of academic impact, for papers by Diana M. Barnes
Rankless by CCL
2026